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Evaluation of Ribavirin Genotoxicity with Sister
Chromatid Exchange and Micronuclei Assays in Humans
Aim: The main objective of this study was to assess the genotoxicity of ribavirin in 15 patients who were
suffering from Crimean–Congo haemorrhagic fever and treated with the therapy dose of the antiviral agent.
Materials and Methods: Genotoxicity was evaluated using the cytokinesis-blocked micronucleus (MN) and
sister chromatid exchange (SCE) assays in lymphocyte cultures that were prepared from blood samples
collected from the 15 patients. The blood samples were taken on day 9 of a 10-day therapeutic regimen of
ribavirin and 1 month after the cessation of therapy.
Results: In all patients, the frequency of sister chromatid exchanges and the formation of micronuclei were
significantly higher in the lymphocytes of blood samples that were taken in day 9 of the therapy compared to
those that were collected 1 month after the cessation of therapy. In addition, on day 9, SCE and MN values
were statistically different from the values of no-ribavirin control group.
Conclusions: These results showed that ribavirin has a reversible genotoxic effect in humans and this effect
could be due to toxic metabolites of ribavirin.

1

Department of Medical Genetics,
Faculty of Medicine,
Atatürk University,
Erzurum - TURKEY

2

Department of Infectious Diseases,
Faculty of Medicine,
Atatürk University,
Erzurum - TURKEY

3

Department of Pharmacology,
Faculty of Medicine,
Atatürk University,
Erzurum - TURKEY

4

Department of Public Health,
Faculty of Medicine,
Atatürk University,
Erzurum - TURKEY

Key Words: Ribavirin, genotoxic effect, sister chromatid exchange, micronuclei formation

İnsanlarda Ribavirin Genotoksisitesinin Kardeş Kromatid Değişimi ve
Mikronükleus Yöntemleri ile Değerlendirilmesi
Amaç: Crimean Congo Hemorrhagic Fever nedeniyle tedavi dozunda ribavirin alan 15 hastada ribavirin
genotoksisitesinin değerlendirilmesi amaçlanmıştır.
Yöntem ve Gereç: Onbeş hastadan alınan kan örneklerinden yapılan lenfosit kültürlerinde kardeş kromatid
değişimi (KKD) ve mikronükleus (MN) yöntemleri kullanılarak genotoksik etki değerlendirildi. On günlük
ribavirin tedavisinin dokuzuncu gününde ve tedavi kesildikten 1 ay sonra kan örnekleri alındı.
Bulgular: Tüm hastalarda, kardeş kromatid değişimi sıklığı ve mikronükleus oluşumu, tedavinin dokuzuncu
gününde alınan kan örneklerinde tedavi kesildikten 1 ay sonra alınan örneklere göre belirgin bir biçimde
yüksekti. Ayrıca, dokuzuncu gün KKD ve MN değerleri ribavirin almamış kontrol grubu değerlerinden
istatistiksel anlamda farklıydı.
Sonuç: Sonuçlarımız göstermiştir ki, ribavirin insanlar üzerinde geri dönüşümlü bir genotoksik etkiye sahiptir
ve bu etki ribavirinin toksik metabolitlerinden kaynaklanmaktadır.
Anahtar Sözcükler: Ribavirin, genotoksik etki, kardeş kromatid değişimi, mikronükleus oluşumu
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Introduction
Ribavirin (RBV) (1–β–D–ribofuranosyl–1,2,4– triazole–3–carboxamide; C8H12N4O5)
is a synthetic purine nucleoside analogue and is used therapeutically as a broad spectrum
antiviral agent (1). It exerts its antiviral action by inhibiting inosine monophosphate
dehydrogenase, thereby preventing replication of some DNA and RNA viruses (2). RBV
has been reported to be beneficial in the treatment of measles, Lassa fever, influenza,
parainfluenza, hepatitis C, and in infections due to herpes virus, respiratory syncytial
virus, and human immunodeficiency virus (HIV), but its therapeutic use is limited
because of its toxicity (3,4). Its adverse effects include hemolytic anemia, hepatotoxicity,
mitochondrial toxicity, and teratogenicity (5-8). It has also been demonstrated that RBV
inhibits osteoblast proliferation in vitro (9). Because of its teratogenic potential, women
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are recommended to use contraceptives for 6 months
after RBV treatment. It has been reported that RBV is not
genotoxic in some studies (10,11). Some other reports
describe it as a potential genotoxin in human in vitro and
experimental animals (12). Recently, Narayana et al.
(2002) demonstrated that RBV is mutagenic to the germ
cells of Wistar rats (13).
The sister chromatid exchange (SCE) and
micronucleus (MN) tests are used to establish the
genotoxic effects of physical and chemical agents (14,15).
SCEs are reciprocal interchanges of DNA replication
products at homologous sites between 2 chromatid arms
within a single chromosome in dividing cells (14,16).
These interchanges occur spontaneously in all cells at a
low rate, and the rate of their formation increases when
DNA is damaged and/or improperly repaired. SCEs can be
detected after incorporating bromodeoxyuridine (BrdU)
into chromosomal DNA for 2 cell cycles.
The MN assay is a quantitative test that detects
structural damage to chromosomes and is now widely
used in genotoxicity studies (15,17). Micronuclei can be
formed when either the intact chromosome or acentric
chromosomal fragments become separated from the
nucleus during mitosis or meiosis, and are seen within a
binucleotide cell after blocking cytokinesis (17,18). The
method is now applied to various cell types to disclose
genetic damage that can be caused by ionizing radiation
or potential genotoxins (19).
In view of the uncertainty of the genotoxic effects of
RBV in humans, we evaluated its genotoxicity using SCE
and MN assays in lymphocytes taken from patients who
were suffering from Crimean–Congo hemorrhagic fever
(CCHF) and treated with RBV.

Materials and Methods
Patients and RBV Dosages
The study involved an experimental group composed
of 15 patients and a control group with 12 healthy
volunteers. All individuals in the study lived in a rural
area, were not habitual smokers or drinkers, and had not
been exposed to any known toxic agents. The patients
were diagnosed as suffering from Crimean–Congo
haemorrhagic fever (CCHF) after a clinical examination
and based on the results of microbiological and routine
242
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clinical laboratory tests. The diagnosis of CCHF for each
patient was confirmed by the detection of
immunoglobulin M seropositivity using an enzyme-linked
immunosorbent assay (ELISA) and/or demonstration of
RNA of the virus using reverse transcriptase polymerase
chain reaction (RT-PCR).
Oral RBV treatment at the dosage recommended by
the World Health Organization was started in all patients
immediately after making a provisional diagnosis of
CCHF, and was continued for 10 days (20). The starting
dose of RBV was 2000 mg, and then followed by 1000
mg RBV every 6 h for the first 4 days and 500 mg RBV
every 6 h during the following 6 days. This dosing
regimen has been used successfully to treat CCHF
(21,22). If necessary, intensive supportive therapy was
added to the RBV treatment and no other antimicrobial
agents were administered to any of the patients. On day
9 of therapy and 1 month after completion of therapy,
2–5 ml samples of peripheral blood were taken from each
individual in the experimental and control groups for use
in the SCE and MN assays.
Control individuals had not taken any drugs in the
previous 6 months.
Sister chromatid exchange (SCE) assay
To determine the frequency of SCE in the
lymphocytes, a 1–2.5 ml sample of peripheral blood from
each individual was added to 5 ml of chromosome
medium B (Biochrom, Berlin, Germany) supplemented
with 5 μg/ml of phytohaemagglutinin (Biochrom). BrdU
(5–bromo–2–deoxyuridine, Sigma, MO, USA) was then
-4
added to each culture (10 M final concentration) and the
cultures were incubated in complete darkness for 72 h at
37 °C. Colchicine (final concentration 0.5 μg/ml, Sigma)
was added to each culture during the last 2 h of the
incubation to block the cells in the metaphase stage of
mitosis. Upon completion of the incubation, each cell
culture was subjected to hypotonic treatment by adding 8
ml of 0.075 M KCl and was maintained for 30 min at 37
°C. Three repetitive fixations of each cell suspension were
then performed with cold methanol/acetic acid (3:1, v/v).
An aliquot of each cell suspension was then dropped onto
a cold slide. The slides were dried at room temperature,
and were then kept in the dark for 3 days after which
they were stained using the fluorescence-Giemsa method
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(23). Initially, slides were treated with 0.5 μg/ml
bisBenzimide (Hoechst 33258, Sigma, USA) for 20 min
and then exposed to UV-A (366 nm wavelength) for 1 h.
The slides were incubated at 65 °C in 2XSSC (1:1, v/v,
0.03M sodium citrate/0.03M NaCl) solution for an hour.
After that they were stained with 5% Giemsa for 10 min.
The slides were coded before analysis (23). The number
of SCEs was counted in at least 30 metaphases in each
sample from each individual. The number of SCEs per
metaphase was scored for each individual.
Micronucleus (MN) assay
In order to determine the number of micronucleated
lymphocytes, a 1–2.5 ml sample of peripheral blood from
each individual was added to 5 ml of chromosome
medium B (Biochrom, Berlin, Germany) supplemented
with 5 μg/ml of phytohaemagglutinin (Biochrom). The
cultures were incubated for 72 h at 37 °C. After 44 h,
4.5 μg/ml of cytochalasin–B (Sigma, MO, USA) was added
to each culture to block cytokinesis (19). Upon
completion of the incubation, each cell culture was then
subjected to hypotonic treatment by adding 8 ml of
0.075 M KCl and was maintained for 7 min at 37 °C.
Three repetitive fixations of each cell suspension were
then performed with methanol/acetic acid (3:1, v/v). An
aliquot of each cell suspension was then dropped onto a
cold slide. The slides were air–dried and kept at room
temperature for 1 day after which they were stained with
5% Giemsa. The frequency of cells with 2 or more
micronuclei was determined after assessing between 800
and 1900 binucleated cells from each cell culture. The
slides were scored using the following scoring criteria
described by Fenech et al. (24); the diameter of the MN
should be less than 1/3 of the main nucleus, MN should
be separated from or marginally overlap with main
nucleus as long as there is clear identification of the
nuclear boundary and MN should have similar staining as
the main nucleus.
Statistical analyses
The mean and standard deviation (SD) were calculated
from the individual results of each assay during therapy
and after the cessation of therapy and of the control
group. The data were analyzed using the Wilcoxon signed
rank sum test. The level of significance was set at 5%.
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Results
The frequency of SCEs in the lymphocytes after 9
days of RBV therapy was significantly higher than that
determined 1 month after the cessation of therapy in 14
out of 15 patients (Z = –3.408, P = 0.001) (Figure 1).
The mean frequency of SCEs on day 9 of therapy was
10.37 ± 2.61 (range: 6.42–15.49). The mean SCE
frequency was 6.02 ± 0.65 (range: 4.78–7.23) 1 month
after the cessation of therapy.
The MN scores in the lymphocytes of the 15 patients
during therapy were significantly higher than those
determined 1 month after the cessation of therapy (Z =
–3.408, P = 0.001). The mean MN scores on day 9 of
therapy was 22.1 ± 0.98 (range: 10.45–38.46) (Figure
2). Furthermore, we found that there was a positive
correlation between the frequency of SCEs and the
number of binucleated cells with micronuclei after day 9
of RBV therapy in the 15 patients. This correlation was
not observed 1 month after the cessation of therapy.
Likewise, there was no correlation between SCE numbers
and prognosis of the patients.


'"

   !  " #!$ &

Vol: 39

*+ < #$ !+
"<#$ ># 






 

   




 

Figure 1. Individual variation in the frequency of SCEs during therapy
and 1 month after the cessation of therapy. Variations
among the cases with respect to differences in the values on
day 9 of therapy and 1 month after the cessation of therapy
are shown.
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than 10 mg/kg (11,13,25). The cytotoxic effect of this
drug is almost certainly due to the induction of cell death
and the suppression of cell division and proliferation (25).
However, it is still controversial whether RBV is genotoxic
in humans, and conflicting results have been reported.
The results of our study have shown that RBV has a
reversible genotoxic effect in humans.
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Figure 2. Individual variation in the formation of micronuclei during
therapy and 1 month after the cessation of therapy.

In the control group, the SCE frequency and MN
scores were 5.71 ± 1.15 and 3.65 ± 0.97, respectively
(Tables 1 and 2). Day 9 group showed significant
difference compared to the control group regarding both
SCE and MN tests (P < 0.0001). However, there were no
statistical differences between the control group and the
experimental group after 1 month of therapy (P >
0.005).

The results of previous studies on the genotoxicity of
RBV are controversial because different methods have
been used to assess its genotoxicity. The measured
toxicity of RBV may depend on whether genotoxicity was
assessed using an in vivo or an in vitro assay because of
the formation of its metabolites, ribavirin–5′–
triphosphate, and ribavirin–5′–monophosphate. These 2
metabolites are more toxic than RBV and are only formed
following in vivo administration of RBV. Therefore, they
are not generated in an in vitro assay system to which
RBV is added (26,27). The type of assay used to assess
RBV toxicity therefore needs to be considered comparing
the results of toxicity studies of RBV. In this investigation,
we used SCE and MN assays to assess the genotoxicity of
RBV in vivo. Therefore, our results encompass the
toxicity of the metabolites as well as that of intact RBV
because we collected blood samples from patients who
were treated with RBV. Our finding that RBV is genotoxic
in humans coincides with previously published in vivo
animal studies (12,28,29).

The results of previous studies on the toxicity of RBV
in humans have demonstrated that RBV is cytotoxic to
numerous cell types, especially erythrocytes,
lymphocytes, and germ cells, when given at doses greater

Hoffmann et al. reported that RBV had no mutagenic
potential in male rats, following the use of the dominant
lethal assay (10). However, this method may not be
sufficiently sensitive to assess the mutagenic potential of
RBV. The dominant lethal effect is the result of
chromosomal damage and it may not be possible to
demonstrate these genomic alterations experimentally, as
they are not fatal to the fertilized egg or the developing
embryo. On the other hand, Narayana et al. showed a
mutagenic effect of RBV on rat germ cells using identical

Table 1. Statistical analyses of SCE frequencies on day 9 of therapy
group, the experimental group 1 month after the cessation,
and the control group.

Table 2. Statistical analyses of MN scores on day 9 of therapy group,
the experimental group 1 month after the cessation, and the
control group.

Discussion

n

Mean ± SD

P

Day 9 of therapy

15

10.37 ± 2.61

P < 0.00011

month after therapy

15

6.02 ± 0.65

P > 0.005

Control

12

5.71 ± 1.15

-
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n

Mean ± SD

P

Day 9 of therapy

15

22.1 ± 0.98

P < 0.00011

month after therapy

15

3.74 ± 1.16

P > 0.005

Control

12

3.65 ± 0.97

-
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doses that were used by Hoffmann et al. (13). In an in
vitro study conducted by Joksic et al., RBV was shown to
suppress cellular proliferation at all the doses used, but it
did not increase micronuclear formation after blocking
cytokinesis in cultured human lymphocytes (11). On the
contrary, the results of another study showed that RBV
increased MN frequency in cultured lymphocytes when
RBV was used at high doses and the cells were exposed
for a long time (30). Using 2 methods to assess its
genotoxicity, we have shown that RBV is a genotoxic
chemical. We are convinced that this conclusion is valid
because different researchers performed each of the 2
genotoxicity assays in order to prevent researcher bias in
the collection and interpretation of the results.
Several investigators have used the MN assay to
evaluate RBV toxicity and have shown that RBV has
mutagenic activity in the bone marrow of mice and rats
when administered at doses greater than 10 mg/kg
(12,28,29). They have also demonstrated that this effect
was not dose-dependent. Narayana et al. did not find a
linear correlation between the administered dose and
toxicity when using the in vivo sperm morphology assay
to assess RBV toxicity, although they found a weak
concentration-dependent effect when they used an in
vitro assay to assess its mutagenicity (13). Joksic et al.,
however, reported the existence of a positive correlation
between the genotoxicity of RBV and its exposure time,
and between its genotoxicity and concentration, using the
MN assay (30). In our study, the combination of time (9
days) and dose (30–50 mg/kg/day) was sufficient to
produce a toxic effect of the drug. We were not able to
investigate the correlation between the dose of RBV and
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its genotoxicity because RBV was administered to the
patients only at the recommended dose. Nevertheless, we
found that there were individual differences in the
severity of genotoxicity at identical doses of
administration and we believe that the individual’s ability
to metabolize the drug accounts for this difference. The
frequency of SCEs and the formation of micronuclei
during treatment were much greater than those found 1
month after the cessation of therapy. There were no
statistical difference between the control group and the
experimental group 1 month after cessation for both SCE
and MN tests (Tables 1 and 2). The frequency of SCEs
during therapy ranged widely, whereas it was within a
very narrow range after therapy. We thus suggest that
individual sensitivity of subjects to RBV can affect the
severity of its genotoxicity.
It is widely accepted that RBV is a cytotoxic and
genotoxic agent (12,31). In our preliminary study, which
included only 3 patients, we proved that RBV may be a
potent genotoxic agent in humans (32). This present
study including a larger number of adult subjects further
supports that RBV is a drug having genotoxic effect. The
results of this study provide further support that RBV is
a drug that has reversible genotoxic effects. There are
insufficient studies on RBV toxicity in humans. To the best
of our knowledge, this is one of the early studies
reporting RBV-induced genotoxicity in humans in vivo.
Because the use of RBV to treat CCHF in all likelihood will
increase (14,33,34), physicians should keep the
genotoxicity of RBV in mind when administering it to
patients, despite the fact that its genotoxic effect appears
to be transient.
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